Boehringer Ingelheim and Click Therapeutics expand collaboration to develop digital therapeutics for schizophrenia

Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData

36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.

Entod Pharmaceuticals to launch GLO division

This one-of-a-kind ophthalmic subspecialty division is focused on the treatment of the eye condition glaucoma

Roche presents new data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022

Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes

Emmes launches Cell and Gene Therapy Center

The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies

Fraunhofer IZI Selects Lonza’s MODA-ES Solution to Digitalize Manufacturing Operations

GMP-compliant documentation of all manufacturing steps for cell and gene therapies

High demand leaves Ozempic compensating for Wegovy’s supply shortage: GlobalData

WuXi STA launches parenteral formulation manufacturing line at Wuxi

This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units

Lonza collaborates with AbTis to extend Bioconjugation capabilities

Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox

Evive enters license agreement with Acrotech Biopharma to commercialize Ryzneuta in US

Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)